Cameron Turtle - 22 Jun 2023 Form 3 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Chief Operating Officer
Signature
/s/ Jonathan Alspaugh, by power of attorney
Issuer symbol
AGLE
Transactions as of
22 Jun 2023
Transactions value $
$0
Form type
3
Filing time
30 Jun 2023, 17:14:04 UTC
Next filing
27 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AGLE Common Stock 577K 22 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGLE Stock Option (Right to Buy) 22 Jun 2023 Common Stock 47.3M $0.30 Direct F2
holding AGLE Series A Preferred Stock 22 Jun 2023 Common Stock 18.1M Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 544,565 shares of Common Stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.
F2 The stock option vests and becomes exercisable in 48 equal monthly installments beginning on June 22, 2023, subject to the continuing service of the Reporting Person on each vesting date.
F3 Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations.
F4 Includes 17,186,000 shares of Common Stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney